This article is more than 5 years old. Information may no longer be current.

VIDEO: Updated HF guidelines focus on ivabradine, sacubitril/valsartan

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

In this video, Nancy Albert, PhD, CNS, of the Cleveland Clinic, discusses her presentation from the AAHFN Annual Meeting on the updated HF guidelines that were released earlier this year.

“The guideline update was very interesting, because the focus was really on two new medications that are FDA-approved and out on the market,” Albert said. These agents include ivabradine (Corlanor, Amgen) and sacubitril/valsartan (Entresto, Novartis).

Albert reviews the patient populations in which these medications can be used, as well as the benefits of each agent. Both ivabradine and sacubitril/valsartan were shown to reduce readmissions in patients with HF; sacubitril/valsartan also demonstrated reduced cardiovascular and all-cause mortality.

“In patients with HF, there’s a new opportunity now to change the class of drug from a vasodilator that we’ve been using for years to a new vasodilator that has some additional benefits that lead to improved outcomes,” Albert said.